# Preimplantation Genetic Diagnosis for DEB by Detecting a Novel Family-Specific COL7A1 Mutation in Vietnam

Sang Trieutien, Tam Vu Van, My Tran Ngoc Thao, Son Trinh The, Khoa Tran Van, Tung Nguyen Thanh, Tuan Tran Van, Hanh Nguyen Thi

► To cite this version:

Sang Trieutien, Tam Vu Van, My Tran Ngoc Thao, Son Trinh The, Khoa Tran Van, et al.. Preimplantation Genetic Diagnosis for DEB by Detecting a Novel Family-Specific COL7A1 Mutation in Vietnam. The application of clinical genetics, 2021, Volume 14, pp.467-472. 10.2147/TACG.S344107. hal-03499593

HAL Id: hal-03499593

https://hal.sorbonne-universite.fr/hal-03499593

Submitted on 21 Dec 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Open Access Full Text Article

ORIGINAL RESEARCH

# Preimplantation Genetic Diagnosis for DEB by Detecting a Novel Family-Specific COL7A1 Mutation in Vietnam

Sang Trieutien<sup>ID 1,*</sup>

Tam Vu Van<sup>2,3,*</sup>

My Tran Ngoc Thao<sup>ID 4</sup>

Son Trinh The<sup>5</sup>

Khoa Tran Van<sup>1</sup>

Tung Nguyen Thanh<sup>5</sup>

Tuan Tran Van<sup>5</sup>

Hanh Nguyen Thi<sup>6</sup>

<sup>1</sup>Department of Biology and Genetics, Vietnam Military Medical University, Hanoi, 12108, Vietnam; <sup>2</sup>Director Office, Hai Phong Hospital of Obstetrics and Gynecology, Haiphong, 40000, Vietnam; <sup>3</sup>Obstetrics and Gynecology Department, Haiphong University of Medicine and Pharmacy, Haiphong, 40000, Vietnam; <sup>4</sup>Département de formation Biologie moléculaire et cellulaire, Sorbonne University, Paris, 75006, France; <sup>5</sup>Military Institute of Clinical Embryology and Histology, Vietnam Military Medical University, Hanoi, 12108, Vietnam; <sup>6</sup>Faculty of Biology, VNU University of Science, Vietnam National University, Hanoi, 12108, Vietnam

**Background:** Epidermolysis bullosa (EB) is a disorder characterized by the appearance of blisters, erosions and wounds in response to minimal trauma. The disease manifests with noticeable symptoms ranging from mild to severe, classified into four major types: epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), dystrophic epidermolysis bullosa (DEB) and Kindler syndrome. Preimplantation genetic diagnosis for the disease remains the only available option for families at risk for the recurrence of the disorder without having to terminate an ongoing pregnancy.

**Materials and Methods:** A novel COL7A1 mutation was used to design primers for the polymerase chain reaction (PCR) to amplify the segment spanning the mutation in the family and their in-vitro fertilization (IVF) embryos. Then, the PCR products were sequenced with Sanger sequencing to detect the alteration in the allele, and some embryos would go through NGS-based preimplantation screening for chromosomal abnormalities.

**Results:** The established protocol for EB detected mutant allele in 6/9 embryos (66.6%), while the remaining 3 embryos (33.4%) appeared to not carry any mutation. Only one among 3 embryos was recommended to be transferred into the mother's uterus.

**Conclusion:** The established preimplantation genetic diagnosis procedure is helpful to families affected by epidermolysis bullosa caused by COL7A1 mutations but wish to have healthy children.

**Keywords:** epidermolysis bullosa, rare dystrophic epidermolysis bullosa, EB, RDEB, skin disorder, COL7A1 gene mutation, preimplantation genetic diagnosis, PGD

## Introduction

Epidermolysis bullosa (EB) constitutes a heterogeneous group of heritable mechano-bullous disorders characterized by the appearance of blisters, erosions and wounds in response to minimal trauma. The disease manifests with noticeable symptoms ranging from mild to severe on the epithelial layer or the mucous membrane. Much has been discovered and changed about the spectrum of inherited EB since it was first defined and classified, with the application of different fields of biology and techniques. Up to date, epidermolysis bullosa comprises four major types depending on the level of skin cleavage: epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), dystrophic epidermolysis bullosa (DEB) and Kindler syndrome.<sup>1,2</sup> The molecular pathology of EB now consists of 21 genes with over 1000 reported pathogenic variants in either an autosomal dominant or autosomal recessive inheritance manner. These mutations lead to the change in

<figure><img src="image_3.png" /></figure>

<footnote>*These authors contributed equally to this work</footnote>

<footnote>Correspondence: Son Trinh The
Military Institute of Clinical Embryology
and Histology, Vietnam Military Medical
University, Hanoi, 12108, Vietnam
Email: trinhthesonart@gmail.com</footnote>
the adhesion among specific attachment proteins or in the dermal-epidermal junction, which would eventually lead to the fragility of the skin.³,⁴

In dystrophic epidermolysis bullosa (DEB), the blistering occurs within the sub-lamina densa region within the uppermost dermis. Two main subtypes of DEB that are classified according to their mode of inheritance, dominant DEB (DDEB) and recessive DEB (RDEB), are only associated with the gene COL7A1. The gene is located within the 3p21 region, spanning about 32 kb and comprising 118 exons.⁵ In fact, they are due to mutations in the COL7A1 gene encoding for the homotrimer type VII collagen, which is the major component of the cutaneous basement membrane's anchoring fibrils.¹,⁶⁻⁸ The defects in the fibrils, such as the morphological alteration, physical reduction or absence, result in a considerable degree of clinical severity based on the different types and positions of the pathogenic variants. The phenotypic variability can highly differ from a limited tendency to blistering or nail dystrophy to severe extra-cutaneous complications, even lethal carcinomas and early mortality.⁸⁻¹⁰

Preimplantation genetic diagnosis (PGD), or in other terms, preimplantation genetic testing for monogenic disorder (PGT-M), is considered to be the earliest form of prenatal testing for couples at reproductive risks with a hereditary disease. Once a pathogenic variant is known, PGD would be performed to examine the cellular material from in-vitro fertilization (IVF) embryos for specific genetic abnormalities before pregnancy. This advanced specialized procedure offers appropriate genetic counseling to determine the genetic risk for future offspring and obviate the need to terminate an affected pregnancy. With the advent of technologies in biology and medicine, the spectrum of PGD is remarkably expanded when approximately 500 different conditions have been interrogated worldwide.¹¹ In the case of DEB, not only are the pathogenic variants distributed over the entire gene making the process of screening COL7A1 gene time-consuming and expensive but also there have not been any effective treatments for the diseases. Thus, early prevention of DEB remains the only available option for families at risk for the recurrence of the disorder.²,¹⁰,¹² Even though developing a standardized PGD procedure is work-intensive, complex and costly, this paper aimed to describe a PGD protocol for RDEB utilizing whole-genome amplification (WGA) and Sanger sequencing. Hence, incorporating these diverse techniques generated a more feasible and economical yet profoundly reliable approach for couples with family-specific pathogenic COL7A1 variants in Vietnam,

producing an exact diagnosis of recessive dystrophic epidermolysis bullosa in future generations.

## Materials and Methods

### Patient Description

A Vietnamese nuclear family enrolled in the study, including a four-year-old son with noticeable characteristics of epidermolysis bullosa. The son was diagnosed with DEB and presented with the occurrence of blisters, scarring and erosion on his shoulder, back, limbs and dystrophic nails while his parents did not present any clinical or genetic alteration of interest. By studying the affected's genetic information with whole-exome sequencing, it was reported that the son carried a recessive homozygous mutation c.8279G>A (p.G2760E) on the exon 111 of the gene COL7A1. This novel non-synonymous variant has never been reported in any public database, which was predicted as probably damaging/deleterious by in silico algorithms, such as SIFT, Polyphen2 and MutationTaster.¹³ With bidirectional Sanger sequencing on his parents' DNA, the heterozygous c.8279G>A variant was also observed.

All people described in this research were signed written informed consent for the publication of the case details, and the protocol was approved by the Ethical Review Committee of Vietnam Military Medical University (No.1068/2019/VMMU-IRB). This study was also conducted using good clinical practice following the Declaration of Helsinki and its later amendments or comparable ethical standards.

## DNA Extraction from Whole Blood

DNA was extracted from the collected blood samples by following the protocol of the G-spin™ Total DNA Extraction Kit (Lot. No. 105260354; Exp. June 2023). DNA went through a quality check process with a SpectraMax QuickDrop to measure the optical density (OD) and A260/A280 index. Hence, the DNA collected from the sample was qualified to be used in the next steps of the research. DNA samples were stored at -20°C.

## Blastocyst Embryo Biopsy

There were nine embryos (number 1 to 9) cultured to the fifth day of the described couple who had done IVF at the Military Institute of Clinical Embryology and Histology (MICEH). Then, the embryos were biopsied (3-5 cells) and washed with PBS 1X and 1% PVP solution. After that,
the washed embryo cells were contained in the 0.2 mL PCR tube. The embryo cells were stored at -20°C.

## Whole Genome Amplification for Embryos' Genome

The DNA from the biopsied embryos was amplified with REPLI-g® Single Cell Kit (Lot. No. 169023130; Exp. May 2022) and then diluted with nuclease-free water. The concentration and purification were calculated with a SpectraMax QuickDrop. Therefore, the amplified DNA collected from the embryonic cells was qualified to be used in the research. DNA samples were stored at -20°C.

## Polymerase Chain Reaction (PCR) Analysis

First, primers were designed to amplify the segment targeting exon 111 and spanning the detected mutation c.8279G>A. Afterward, a PCR was performed by using the designed primers and DNA collected from the whole family and DNA amplified from biopsied embryonic cells to confirm the inheritance of mutation. PCR products were then electrophoresed on 2% agarose gel on multiSUB Choice, Wide Midi Horizontal Electrophoresis System (Cleaver Scientific, SKU: MSCHOICE10) to check for the appropriate desired products.

## Sanger Sequencing and the Next-Generation Sequencing Analysis

The amplified PCR products showing the accurate bands on electrophoresis results would be sequenced by Sanger sequencing to scan for the c.8279G>A mutation. The process was carried out on the ABI 3500 Genetic Analyzer according to the manufacturer's instructions. Next, embryos that do not carry any mutated alleles would go through preimplantation genetic aneuploidy testing (PGT-A) based on Thermo Fisher Scientific Ion

Proton™ semiconductor system, using the clinical testing kits to screen for chromosomal abnormalities. Then, the obtained next-generation sequencing data would be analyzed automatically with the manufacturer's software.

## Results

### Preimplantation Genetic Diagnosis Program for DEB

The PCR reaction utilizing the appropriate primers, components and the thermal cycle was performed in triplicate. After each reaction round, the products went under electrophoresis on 2% agarose gel and were observed under UV light. The obtained results were consistent in all reactions. The gel electrophoresis was then analyzed, resulting in the successful amplification of all desired gene segments in all samples and embryos in comparison to the positive control that was the DEB homozygotes. The products' bands appeared bright and clear at a position corresponding to the standard scale size of around 250 base pairs, proving that the amplified segment was consistent with the initial expectation of 241 base pairs. From here, the PCR products would be purified and sequenced via the Sanger sequencing method to detect the c.8279G>A variant in these cells.

### Sanger Sequencing and NGS Results

Sanger sequencing was carried out using forward and reverse primers to amplify the segment spanning exon 111 from both ends in order to ensure the accurate interpretation of the results. The Sanger sequencing's electropherograms were annotated by SnapGene software and summarized in Table 1.

From the information provided by Sanger sequencing, among nine biopsied embryos, two of which (22.2%) were DEB homozygotes, while four (44.4%) were DEB carriers. In fact, these embryos inherited at least one pathogenic

<table><caption>**Table 1** Genotypes of Nine IVF Embryos by Sanger Sequencing</caption><thead><tr><td>Embryos Number</td><td>Genotype</td><td>Diagnosis</td><td>Embryos Number</td><td>Genotype</td><td>Diagnosis</td></tr></thead><tbody><tr><td>No. 1</td><td>c.8279G>A/c.8279G>A</td><td>DEB</td><td>No. 6</td><td>wt/wt</td><td>Normal</td></tr><tr><td>No. 2</td><td>wt/wt</td><td>Normal</td><td>No. 7</td><td>c.8279G>A/c.8279G>A</td><td>DEB</td></tr><tr><td>No. 3</td><td>c.8279G>A/wt</td><td>DEB carrier</td><td>No. 8</td><td>wt/wt</td><td>Normal</td></tr><tr><td>No. 4</td><td>c.8279G>A/wt</td><td>DEB carrier</td><td>No. 9</td><td>c.8279G>A/wt</td><td>DEB carrier</td></tr><tr><td>No. 5</td><td>c.8279G>A/wt</td><td>DEB carrier</td><td></td><td></td><td></td></tr></tbody></table>
allele from either the mother or the father, whose geno-
types were determined to be heterozygous according to
Sanger sequencing. Although the embryos that carried one
mutant allele for DEB might not develop any clinical
symptoms later in life, these embryos, along with the
mutant homozygotes, were advised not to be transferred
to completely prevent the inheritance of the pathogenic
variant. The remaining embryos number 2, 6 and 8 were
recommended to carry out PGT-A to screen for any chro-
mosomal abnormalities to reduce the risk of miscarriage
and to increase the possible pregnancy and live birth rate.

Based on the obtained NGS results of the Ion Proton™ system, embryos number 2 and 6 observed a trisomy pattern in chromosomes 15 and 21, respectively. Embryo number 8 was found not to carry any aneuploidies; therefore, it could be concluded that this embryo should be selected for transfer.

Discussion

The variant c.8279G>A (p.G2760E) that was first found in
the son was reported to be a novel variant by Whole
Exome Sequencing. This substitution mutation of the
amino acid glycine by glutamic acid happens on the col-
lagenous encoding domain, which might affect the pro-
tein's stability and its triple helix structure.¹³ Since the
variant was discovered, the genetic information of both
parents was thoroughly studied to exclude the possibility
of a de novo mutation, mainly when his mother and father
did not express any clinical symptoms regarding dys-
trophic epidermolysis bullosa. Indeed, the pathogenic var-
iant was identified in both of them with one copy of the
mutated allele, consequently transmitted to their firstborn,
leading to his current state. The disease leaves significant
psychological and physical morbidity for the patients'
families since the couples constantly fear the recurrence
of RDEB in the future offspring, especially when unfami-
liar with genetic services. Therefore, the need to promote
the advantages of PGD or PGT-M for the affected families
is growing tremendously to help the ones in need.

PGT-M is a robust and highly specialized procedure
involving the testing of genetic material in IVF human
embryos. It begins with the stimulation of the ovaries to
collect oocytes, then fertilization by sperm injection
(ICSI). Then, the embryos are biopsied at different stages
of development, either by a single blastomere at the clea-
vage stage or multiple trophectoderm (TE) at the blasto-
cyst stage. However, a blastocyst stage biopsy is becoming
preferable in terms of PGD approaches across the globe.

The reason behind this trend is that more cells can be
removed at this stage, which means there would be higher
DNA yield to carry out more accurate diagnosis yet does
not affect the blastocyst viability if appropriately per-
formed by experienced hands.¹¹,¹⁴⁻¹⁷ Accordingly, much
effort has been made to establish a feasible and widely
applicable preimplantation genetic diagnosis procedure
using advanced biopsy and genetic analysis techniques.
In literature, various studies are focusing on the early
detection of different types of epidermolysis bullosa. All
the designed tests had to reflect the complexity of the
disease's molecular pathology, which comprises mutations
spanning almost every exon of the gene COL7A1. In each
case, the discovered pathogenic variants are rarely recur-
rent yet specific to individual families, sometimes
novel.¹⁸⁻²⁰

Moreover, some other researches also focused on poly-
morphic markers within and flanking the genes responsible
for other EB types, such as junctional epidermolysis
bullosa.²¹,²² Therefore, in EB, where mutation screening
in preimplantation genetic diagnosis is not convenient and
economical, an approach utilizing a straightforward analy-
sis tool for a specific mutation is more applicable and
practical. In our research, based on discovering the muta-
tion of exon 111, a set of primers were designed for both
conventional PCR programs and direct sequencing of the
PCR products. Since one pair of primers was needed to
detect the novel family-specific variant, the labor for car-
rying out the diagnosis has decreased immensely. At the
same time, the test's accuracy is strengthened, and it can
be applied to other couples in the same family.

Apart from developing the general idea behind this
PGD procedure, some common technical obstacles had to
be overcome regarding single-cell assay. These problems
include insufficient DNA template, amplification failure,
or allele dropout.²³⁻²⁵ However, using a non-PCR-based
amplification technique called multiple displacement
amplification (MDA), adequate DNA was generated uni-
formly with high molecular weight and large fragments.
The high processivity and excellent proofreading activity
exploited from Phi29 DNA polymerase pose a greater
possibility of developing a robust and non-bias amplifying
procedure for limited DNA sources.²⁶,²⁷ Moreover, incor-
porating one more round of DNA targeting the exon with
the mutation with specifically designed primers would
diminish the amplification failure for further analysis.
Nonetheless, a small fraction of erroneous diagnoses
occur, mainly caused by ADO as directly working on the
embryos' genetic materials is not practical; hence, this raises a problematic issue regarding preimplantation testing for in vitro fertilization processes. The false-negative result, especially in recessive Mendelian disorders, has always been the main concern for IVF practitioners, genetic specialists, and patients and should be avoided at all costs.

Overall, our research focused on developing a contemporary procedure to balance between giving out the best results in genetic consultations and ensuring the highest vitality of in vitro fertilized embryos. Blastocyst stage TE biopsy, multiple displacement amplification, then performing both PGT-M to detect epidermolysis bullosa and PGT-A for chromosomal abnormalities make up for each other's shortcomings when being applied individually. The utilization of Sanger sequencing – an exact sequencing technique – enables a fast and reliable approach to studying each nucleotide of the pathogenic variant's exon. With its improvements in methodology and automation, this is irrefutably suitable for examining single nucleotide replacement in a short segment. In addition, by coordinating NGS-based PGT-A on amplified DNA from human embryos, embryonic mosaicism can be identified in whole chromosomes as well as segmental regions along with aneuploidy and structural rearrangements. Thanks to the advent of bioinformatics tools, PGT-A technology has been widely adopted by various assisted reproduction centers. It has been reported to increase rates of positive clinical outcomes compared to transfers without PGT-A in some studies. According to Sacchi et al, the live birth rate per transferred embryo was significantly higher in the PGT-A group (40.3%) than in the control group (11.0%). Moreover, much higher aneuploidy in the control group was witnessed in cytogenetic analysis of amniocentesis products compared to PGT-A (0% versus 17.9% and 19.9%).²⁸ Furthermore, the application of PGT-A on elective single embryo transfer (eSET) has tremendously improved implantation rates despite only one embryo being transferred since it considerably decreased the complications from multiple pregnancies.²⁹⁻³¹ Although NGS-based PGT-A should be offered to patient groups with a high incidence of embryonic aneuploidy, evidence demonstrates that it likewise benefits young and good-prognosis patients.³²,³³ It not only reduced the risks of miscarriage but also time to pregnancy. Additionally, it helped increase the live births rate and enabled confident single embryo transfer, even for patients younger than 35 years old.³⁴

## Conclusion

The established PGD procedure is helpful to families affected by epidermolysis bullosa caused by COL7A1 mutations. With proper counseling towards the hereditary disease, couples at reproductive risk for recurrence of EB would be in an active state to make plans for their future offspring without the inheritance of the pathogenic allele. Incorporating advances in molecular techniques provide patients and their families with a robust, precise, and cost-effective mutation detection process that is practical among genetic centers worldwide.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Fine J-D, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. *J Am Acad Dermatol.* 2014;70(6):1103-1126. doi:10.1016/j.jaad.2014.01.903

2. Järvikallio A, Pulkkinen L, Uitto J. Molecular basis of dystrophic epidermolysis bullosa: mutations in the type VII collagen gene (COL7A1). *Hum Mutat.* 1997;10(5):338-347. doi:10.1002/(SICI)1098-1004(1997)10:5<338::AID-HUMU2>3.0.CO;2-B

3. Vahidnezhad H, Youssefian L, Saeidian AH, Uitto J. Phenotypic spectrum of epidermolysis bullosa: the paradigm of syndromic versus non-syndromic skin fragility disorders. *J Investig Dermatol.* 2019;139(3):522-527. doi:10.1016/j.jid.2018.10.017

4. Has C, Fischer J. Inherited epidermolysis bullosa: new diagnostics and new clinical phenotypes. *Exp Dermatol.* 2019;28(10):1146-1152. doi:10.1111/exd.13668

5. Christiano AM, Hoffman GG, Chung-Honet LC, et al. Structural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene. *Genomics.* 1994;21(1):169-179. doi:10.1006/geno.1994.1239

6. Uitto J. The molecular basis of the dystrophic forms of epidermolysis bullosa. In: *Epidermolysis Bullosa Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry*; 1999.

7. Uitto J, Pulkkinen L. The genodermatoses: candidate diseases for gene therapy. *Hum Gene Ther.* 2000;11(16):2267-2275. doi:10.1089/104303400750035807

8. Mariath LM, Santin JT, Frantz JA, Doriqui MJR, Schuler-Faccini L, Kiszewski AE. Genotype-phenotype correlations on epidermolysis bullosa with congenital absence of skin: a comprehensive review. *Clin Genet.* 2021;99(1):29-41. doi:10.1111/cge.13792

9. Varki R, Sadowski S, Uitto J, Pfendner E. Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes. *J Med Genet.* 2007;44(3):181-192. doi:10.1136/jmg.2006.045302

10. Kern JS, Kohlhase J, Bruckner-Tuderman L, Has C. Expanding the COL7A1 mutation database: novel and recurrent mutations and unusual genotype-phenotype constellations in 41 patients with dystrophic epidermolysis bullosa. *J Investig Dermatol.* 2006;126(5):1006-1012. doi:10.1038/sj.jid.5700219

11. Simpson JL, Kuliev A, Rechitsky S. Overview of preimplantation genetic diagnosis (PGD): historical perspective and future direction. In: *Prenatal Diagnosis*; 2019:23-43.
12. Uitto J, Pulkkinen L, Ringpfeil F. Progress in molecular genetics of heritable skin diseases: the paradigms of epidermolysis bullosa and pseudoxanthoma elasticum. Journal of Investigative Dermatology Symposium Proceedings. Elsevier; 2002:6–16.

13. Ma THT, Luong TLA, Hoang TL, et al. Novel and very rare causative variants in the COL7A1 gene of Vietnamese patients with recessive dystrophic epidermolysis bullosa revealed by whole-exome sequencing. *Mol Genet Genomic Med.* 2021;9(8):e1748. doi:10.1002/mgg3.1748

14. Coonen E, Van Montfoort A, Carvalho F, et al. ESHRE PGT Consortium data collection XVI–XVIII: cycles from 2013 to 2015. *Hum Reprod Open.* 2020;2020(4):hoaa043. doi:10.1093/hropen/hoaa043

15. Sciorio R, Tramontano L, Catt J. Preimplantation genetic diagnosis (PGD) and genetic testing for aneuploidy (PGT-A): status and future challenges. *Gynecol Endocrinol.* 2020;36(1):6–11. doi:10.1080/09513590.2019.1641194

16. Committee EPCS, Carvalho F, Coonen E, et al. ESHRE PGT Consortium good practice recommendations for the organisation of PGT. *Hum Reprod Open.* 2020;2020(3):hoaa021. doi:10.1093/hropen/hoaa021

17. Viotti M. Preimplantation genetic testing for chromosomal abnormalities: aneuploidy, mosaicism, and structural rearrangements. *Genes.* 2020;11(6):602. doi:10.3390/genes11060602

18. Fassihi H, Renwick P, Black C, McGrath J. Single cell PCR amplification of microsatellites flanking the COL7A1 gene and suitability for preimplantation genetic diagnosis of Hallopeau-Siemens recessive dystrophic epidermolysis bullosa. *J Dermatol Sci.* 2006;42(3):241–248. doi:10.1016/j.jdermsci.2006.01.005

19. Ozge A, Safak H, Ebru H, et al. First successful preimplantation genetic diagnosis of epidermolysis bullosa with pyloric atresia: case study of a novel c. 4505-4508insACTC mutation. *J Assist Reprod Genet.* 2012;29(4):347–352. doi:10.1007/s10815-012-9728-8

20. Vendrell X, Bautista-Llácer R, Alberola TM, et al. Pregnancy after PGD for recessive dystrophic epidermolysis bullosa inversa: genetics and preimplantation genetics. *J Assist Reprod Genet.* 2011;28(9):825–832. doi:10.1007/s10815-011-9601-1

21. Cserhalmi-Friedman P, Tang Y, Adler A, Krey L, Grifo J, Christiano A. Preimplantation genetic diagnosis in two families at risk for recurrence of Herlitz junctional epidermolysis bullosa. *Exp Dermatol.* 2000;9(4):290–297.

22. Fassihi H, Liu L, Renwick P, Braude P, McGrath J. Development and successful clinical application of preimplantation genetic haplotyping for Herlitz junctional epidermolysis bullosa. *Br J Dermatol.* 2010;162(6):1330–1336.

23. Thornhill AR, Snow K. Molecular diagnostics in preimplantation genetic diagnosis. *J Mol Diagn.* 2002;4(1):11–29. doi:10.1016/S1525-1578(10)60676-9

24. Thornhill AR, deDie-Smulders C, Geraedts JP, et al. ESHRE PGD Consortium 'Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)'. *Hum Reprod.* 2005;20(1):35–48. doi:10.1093/humrep/deh579

25. Harton G, De Rycke M, Fiorentino F, et al. ESHRE PGD consortium best practice guidelines for amplification-based PGD. *Hum Reprod.* 2011;26(1):33–40. doi:10.1093/humrep/deq231

26. Spits C, Le Caignec C, De Rycke M, et al. Optimization and evaluation of single-cell whole-genome multiple displacement amplification. *Hum Mutat.* 2006;27(5):496–503. doi:10.1002/humu.20324

27. Ling J, Zhuang G, Tazon-Vega B, et al. Evaluation of genome coverage and fidelity of multiple displacement amplification from single cells by SNP array. *Mol Hum Reprod.* 2009;15(11):739–747. doi:10.1093/molehr/gap066

28. Sacchi L, Albani E, Cesana A, et al. Preimplantation genetic testing for aneuploidy improves clinical, gestational, and neonatal outcomes in advanced maternal age patients without compromising cumulative live-birth rate. *J Assist Reprod Genet.* 2019;36(12):2493–2504. doi:10.1007/s10815-019-01609-4

29. Forman EJ, Hong KH, Franasiak JM, Scott RT Jr. Obstetrical and neonatal outcomes from the BEST Trial: single embryo transfer with aneuploidy screening improves outcomes after in vitro fertilization without compromising delivery rates. *Am J Obstet Gynecol.* 2014;210(2):157. e1–157. e6. doi:10.1016/j.ajog.2013.10.016

30. Penzias A, Bendikson K, Butts S, et al. The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion. *Fertil Steril.* 2018;109(3):429–436. doi:10.1016/j.fertnstert.2018.01.002

31. Zakaria M, Ennaji M, Wassym SR, et al. PGT-A for embryos for transfer and to improve clinical outcomes in terms of embryo implantation, and recommendations embryo biopsy for at blastocyst stage. *J Basic Clin Reprod Sci.* 2020;9(5). doi:10.4103/2278-960X.1945146

32. Franasiak JM, Forman EJ, Hong KH, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. *Fertil Steril.* 2014;101(3):656–663. e1. doi:10.1016/j.fertnstert.2013.11.004

33. Rubio C, Rodrigo L, Garcia-Pascual C, et al. Clinical application of embryo aneuploidy testing by next-generation sequencing. *Biol Reprod.* 2019;101(6):1083–1090. doi:10.1093/biolre/ioz019

34. Anderson R, Whitney J, Schiewe M. Clinical benefits of preimplantation genetic testing for aneuploidy (PGT-A) for all in vitro fertilization treatment cycles. *Eur J Med Genet.* 2020;63(2):103731. doi:10.1016/j.ejmg.2019.103731

## The Application of Clinical Genetics

Dovepress

## Publish your work in this journal

The Application of Clinical Genetics is an international, peer-reviewed open access journal that welcomes laboratory and clinical findings in the field of human genetics. Specific topics include: Population genetics; Functional genetics; Natural history of genetic disease; Management of genetic disease; Mechanisms of genetic disease;

Counselling and ethical issues; Animal models; Pharmacogenetics; Prenatal diagnosis; Dysmorphology. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/the-application-of-clinical-genetics-journal